Table 1.

Characteristics of included studies

Study	Country	Sample size	Type of treatment	Range time-to-enrollment (mon)
Grijalva et al., 2010	Mexico	8 Cervical	4-Aminopyridine	24–132
		4 Thoracic
Lima et al., 2010	Portugal	13 Cervical	Olfactory mucosal cells + rehabilitation	18–189
		7 Thoracic
Rao et al., 2013	China	8 Cervical	Olfactory ensheathing cells	8–15
Chen et al., 2014	China	5 Cervical	3 Olfactory ensheathing cells	62–165
			1 Schwann cells
			1 Olfactory ensheathing cells + Schwann cells
		Control arm: 2 Cervical	Placebo	16–186
El-Kheir et al., 2014	Egypt	10 Cervical	Autologous bone marrow-derived cells + rehabilitation	12–36
		40 Thoracic
		Control arm: 5 Cervical	Placebo rehabilitation	N/A
		10 Thoracic
Mendonca et al., 2014	Brazil	13 Thoracic	Bone marrow-derived mesenchymal stem cells + rehabilitation	18–180
Shin et al., 2015	South Korea	19 Cervical	Human neural stem/progenitor cells	0.5–7.1
		Control arm: 15 Cervical	Placebo	0.25–6
Hur et al., 2016	South Korea	7 Cervical	Adipose-derived mesenchymal stem cells	3–28
		6 Thoracic
Vaquero et al., 2016	Spain	12 Thoracic	Bone marrow-derived mesenchymal stem cells	38–321

N/A: Not available.